-+ 0.00%
-+ 0.00%
-+ 0.00%

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting

Barchart·09/23/2026 00:30:00
Listen to the news

Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the Combi-TED Phase 2 international clinical trial of Tedopi® in metastatic Non-Small Cell Lung Cancer sponsored by FoRT have been selected for an oral presentation at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain (October 23-27, 2026).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.